Cellebrite DI (NASDAQ:CLBT) Sets New 52-Week Low – Time to Sell?

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) hit a new 52-week low during trading on Thursday . The company traded as low as $10.55 and last traded at $10.1960, with a volume of 908842 shares. The stock had previously closed at $15.25.

Analyst Ratings Changes

Several analysts recently weighed in on CLBT shares. Needham & Company LLC cut their price target on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Finally, DA Davidson raised their target price on shares of Cellebrite DI from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, Cellebrite DI presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.80.

Cellebrite DI Trading Down 36.3%

The business has a fifty day simple moving average of $14.59 and a two-hundred day simple moving average of $14.09. The stock has a market cap of $2.42 billion, a PE ratio of 34.76, a P/E/G ratio of 1.99 and a beta of 1.18.

Insider Activity at Cellebrite DI

In related news, CEO Thomas E. Hogan sold 103,188 shares of Cellebrite DI stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the sale, the chief executive officer directly owned 590,777 shares in the company, valued at $9,310,645.52. The trade was a 14.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO David Barter sold 41,734 shares of the company’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the completion of the sale, the chief financial officer directly owned 334,219 shares in the company, valued at approximately $5,474,507.22. The trade was a 11.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 157,810 shares of company stock worth $2,475,185 over the last ninety days. 5.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Cooper Creek Partners Management LLC bought a new position in shares of Cellebrite DI during the third quarter valued at approximately $55,999,000. Capital International Investors bought a new stake in shares of Cellebrite DI in the 4th quarter worth approximately $41,073,000. Invesco Ltd. boosted its position in shares of Cellebrite DI by 58.6% in the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock worth $103,030,000 after purchasing an additional 2,054,644 shares in the last quarter. Weiss Asset Management LP grew its stake in shares of Cellebrite DI by 3,485.3% in the 1st quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock worth $26,180,000 after buying an additional 1,846,851 shares during the last quarter. Finally, Artisan Partners Limited Partnership purchased a new stake in shares of Cellebrite DI in the 4th quarter worth approximately $25,871,000. 45.88% of the stock is currently owned by institutional investors.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.